| Literature DB >> 31720191 |
Pooja Patel1, Hira Hussain2, John Fahey1.
Abstract
Ankylosing spondylitis is an inflammatory condition involving the axial spine, often associated with the human leukocyte antigen (HLA)-B27 genotype and supporting radiographic imaging findings. Patients develop symptomatic low back and/or hip pain beginning in late adolescence or early adulthood. Diagnosis of ankylosing spondylitis is based primarily on clinical presentation and imaging studies. In this article, we are presenting a case of a 40-year-old male patient who presented to the office with chief concerns of chronic mid-thoracic back pain and restricted range of motion of his neck. The imaging study obtained was suggestive of fusion of the sacroiliac joints. This article also highlights the presence of elevated inflammatory markers in the setting of the patients chronic symptomatic complaints which could have guided in early diagnosis.Entities:
Keywords: ankylosing spondylitis; chronic low back pain; inflammatory arthritis; inflammatory markers; iritis; spondyloarthropathy; stiffness
Year: 2019 PMID: 31720191 PMCID: PMC6823060 DOI: 10.7759/cureus.5723
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Rheumatologic serology laboratory test results
NA - not applicable; units/mL - units per milliliter; mg/dL - milligram per deciliter; mm/hour - millimeter per hour
| Component | Normal reference range | Eight years ago | Six years ago | Five years ago | Two years ago | Recent |
| Erythrocyte sedimentation rate | 0-20 mm/hour | 22 | 20 | 24 | 44 | 26 |
| C-reactive protein | < 1.0 mg/dL | NA | 3.1 | 2.6 | 3.3 | NA |
| Cyclic citrulline peptide antibody | <20 units | 2 | NA | NA | 3 | NA |
| Rheumatoid factor | <15 Units/mL | <20 | NA | NA | <10 | NA |
| Antinuclear antibody screen | Negative | Negative | NA | NA | NA | NA |
Figure 1X-ray Image of the sacroiliac spine
Findings: There appears to be a fusion of the sacroiliac (SI) joints (yellow circles). There is a marked narrowing of the left hip joint (red circle). There is a hip resurfacing prosthesis on the right.
Impression: There is a fusion of the SI joints. Prominent degenerative change and narrowing of the left hip joint. Resurfacing prosthesis on the right hip.
Figure 2X-ray of the lumbar spine
Findings: The heights of the lumbar vertebral bodies are normal. There are degenerative facet changes at lumbar spinal (L) levels 4 and 5 (L4-5). Mild narrowing of lumbar spine level 5 and sacral disc 1 space (L5-S1) (image C, orange circle). There is some anterior spurring of L4-L5 (image B, blue arrow) and at L1-L2. Remaining lumbar disks are well preserved.
Impression: Degenerative changes as described above. Findings are most marked in the facets at L4 and L5. There is no evidence of vertebral fracture.
Figure 3X-ray of the cervical spine
Findings: The heights of the cervical vertebral bodies are normal. There is the mild narrowing of the cervical C2-C3 disc space. There is a mild anterior spurring at the cervical C3-C4 disc levels. There does not appear to be significant narrowing. Remaining cervical disc spaces are fairly well-preserved. There are mild degenerative facet changes in the mid and upper cervical spine. The odontoid appears intact.
Impression: Mild degenerative disc changes. Degenerative facet changes. There is no evidence of cervical spine fracture.
Extra-articular manifestations of ankylosing spondylitis
| System Involved | Presentation |
| Musculoskeletal: | |
| Axial Involvement | Axial involvement predominates; initially is symmetric, involving the sacroiliac joints and lower spine, progressing cranially; does not skip regions |
| Peripheral Involvement | Peripheral involvement consists of enthesitis; may have asymmetric large joint oligoarthritis, including hips and shoulders; hip involvement causes significant functional limitations; dactylitis is uncommon |
| Dermatologic: | Skin findings are not characteristic; psoriatic like lesions may occasionally occur |
| Ophthalmologic: | Anterior uveitis |
| Gastrointestinal: | Asymptomatic intestinal ulcerations |
| Genitourinary: | Urethritis |
| Cardiovascular: | Aortic valve disease; aortitis; conduction abnormalities; coronary artery disease |
| Pulmonary | Restrictive lung disease from costovertebral rigidity; apical fibrosis |
| Bone Quality | Falsely elevated bone mineral density from syndesmophytes; increased risk of spine fracture |
Differential diagnosis of ankylosing spondylitis
N/A - not applicable
| Diagnosis: | Clinical presentation: | Investigations: | Key points for ankylosing spondylitis: |
| Lumbar strain or muscle spasm | Acute onset often with precipitating event. | N/A | Often reports a history of chronic skeletal pain. |
| Herniated disc | Acute onset with pain radiating below the knee, often associated with neurological deficits (numbness, tingling, weakness, or absent or decreased deep tendon reflexes). | Magnetic resonance imaging of the lumbar spine. | Reports a history of chronic arthropathy. |
| Osteoarthritis | Pain is aggravated with activity, and often has an absence of inflammatory symptoms. | Radiographic evaluation suggestive of asymmetric joint-space narrowing, subchondral sclerosis, osteophytes, and bony cysts. | Ankylosing spondylitis pain improves with movement and has an association with inflammatory symptoms. |
| Rheumatoid arthritis | Predominantly involves multiple, small, peripheral joints of the hands and feet. Usually spares the sacroiliac joints with little effect on the rest of the spine except for cervical spines 1 and 2. | Elevated inflammatory markers, positive rheumatoid factor and cyclic citrulline Peptide antibody. Occasionally, positive antinuclear antibody screen. | Predominately involves the sacroiliac joints. |
| Psoriatic arthritis | Involves multiple peripheral joints, in addition to erythematous sharply defined plaques. | Clinical diagnosis | Ankylosing spondylitis may occasionally present with concomitant psoriasis. |
| Reactive arthritis (formerly known as Reiter's syndrome) | Usually presents with symptoms of sporadic arthritis, urethritis and/or conjunctivitis. | Complete blood count, liver panel, urinalysis, urine culture and sensitivity, nucleic acid amplification assay test for chlamydia and gonorrhea, antinuclear antibody screen, human leukocyte antigen B27, parvovirus antibody screen. | Ankylosing spondylitis symptoms are insidious onset, characterized with history of chronic pain. |
| Irritable bowel disease | Reports a history of abdominal pain/tenderness, diarrhea, bleeding per rectum, malaise, fatigue, arthralgia, iritis, uveitis. | Inflammatory markers, stool examination for bacterial culture, ova and parasite, Clostridium difficile toxins, computed tomographic study of the abdomen and pelvis, colonoscopy. | Ankylosing spondylitis may or may not present with symptoms of irritable bowel disease. |
Medical management of ankylosing spondylitis
| Treatment | Recommendation | Note |
| Non-steroidal anti-inflammatory drugs | Celecoxib (Celebrex®) 100 to 200 milligrams once or twice a day; diclofenac (Voltaren®) 25 to 50 milligrams, two to four times a day; etodolac (Lodine®) 200 to 500 milligrams twice a day; ibuprofen (Motrin®, Advil®) 400 to 800 milligram, three to four times a day; indomethacin (Indocin®) 25 to 50 milligrams, three to four times a day; meloxicam (Mobic®) 7.5 to 15 milligrams, once or twice a day; nabumetone (Relafen®) 500 to 750 milligrams, once a day; naproxen (Aleve®) 220 milligrams twice a day; naproxen (Naprosyn®) 250 to 500 milligrams twice a day; piroxicam (Feldene®) 10 to 20 milligrams once a day; sulindac (Clinoril®) 150 to 200 milligrams one to two times a day. | All non-steroidal anti-inflammatory drugs have the potential to cause upset stomach, peptic ulcer disease, internal bleeding, heart damage, and kidney damage. |
| Tumor necrosis factor inhibitors | Etanercept 50 milligrams per 0.5-milliliter injection once a week subcutaneously; adalimumab 40 milligrams per 40-milliliter injection every other week subcutaneously; infliximab 5 milligrams per kilogram every 6-8 weeks intravenously; golimumab 50-milligram injection once a month subcutaneously; certolizumab 200 milligrams injection every other week subcutaneously. | Too much tumor necrosis factor leads to inflammation. Levels of this substance are increased in autoimmune diseases like ankylosing spondylitis. Tumor necrosis factor inhibitors are antibodies made from human or animal tissue to keep tumor necrosis factor levels steady. Patients are at increased risk of infection, lymphoma, or tuberculosis. Recommend screening patients with a skin test and a chest x-ray before beginning therapy. |
| Disease-modifying anti-rheumatic drugs | Sulfasalazine 1000 milligrams twice a day orally; secukinumab (Cosentyx®) with a loading dose of 150 mg at weeks 0, 1, 2, 3 and 4 and then every four weeks thereafter; methotrexate once a week. | Sulfasalazine may cause yellow/orange urine or skin. Secukinumab - human Immunoglobulin G1k monoclonal antibody that binds to interleukin 17A. Methotrexate may cause swollen gums or mouth sores. |
Prognostic indicators in patients with ankylosing spondylitis
| Prognostic indicators in patients with ankylosing spondylitis: |
| Hip arthritis |
| Sausage-like fingers or toes |
| High erythrocyte sedimentation rate (>30 millimeter per hour) |
| Limitation in range of motion of the lumbar spine |
| Oligoarthritis |
| Onset less than 16 years of age |